In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate cancer, according to an industry press release. As Healio previously reported, ...

The U.S. Food and Drug Administration on Friday approved a new ​formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving ‌scanning access through increased production ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...

Abstracts presented at ASCO GU examined whether the radioligand therapy impacts or is affected by ARPIs or chemotherapy.

Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...

Read more about the under-prescription of first-line treatments for erectile dysfunction in patients with prostate cancer.

The anti-parasitic drug became a household name during the COVID-19 pandemic, and it is now being embraced as an alternative ...